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E.  Practices at risk of inappropriateness in drug holiday  
(temporary suspension vs therapeutic suspension for patients  
at risk of MRONJ). Yes vs No
The Drug Holiday is a controversial issue (due to inconsistent literature data), 
involving both drug prescribers (e.g. oncologists, hematologists, bone health 
specialists, general practitioners) and oral and dental specialists. Consequently, 
some assumptions are to be underlined.
“Drug holiday” can have di!erent meanings in medical literature when referred 
to MRONJ. We have to distinguish:
a) Temporary and preventative suspension of drug therapy (e.g. bisphospho-
nates, denosumab, and sometimes antiangiogenic drugs) in a patient at 
risk of MRONJ, in case of dentistry procedures (e.g. tooth extraction or 
jawbone surgery) potentially inducing or highlighting jawbone necrosis 
(with/without bone exposure); frequently the feared MRONJ risk is due 
to both prolonged treatment and bone trauma;
b) Suspension of drug therapy (e.g. bisphosphonates, denosumab) after 
established diagnosis of MRONJ, hypothetically finalized to stop or to 
slow osteonecrosis process;
c) Suspension of drug therapy (bisphosphonates, denosumab) potentially 
inducing MRONJ after a supposed unfavorable cost-benefit balance, due 
to lowered e"cacy or increased real (or feared) side e!ects; for example, 
due to fear of MRONJ or atypical femur fracture after several years of 
bisphosphonate or denosumab treatment.
As the second and the third meaning have scarce literature data at this 
moment, this document will only a!ord the first meaning of “drug holiday”.
Two di!erent populations are usually recognized as at risk of MRONJ due to 
antiresorptive treatment (e.g. bisphosphonates, denosumab), even with very 
di!erent MRONJ incidence:
i) Cancer and myeloma patients with bone disease receiving antiresorptive 
drugs at higher doses and more frequently (e.g. monthly 4mg i.v. zole-
dronic acid, or monthly 120mg s.c. denosumab administration);
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ii) Osteometabolic patients and people a!ected by other nonmalignant 
diseases (osteoporosis, Paget disease, etc.) receiving antiresorptive drugs 
at lower doses and less frequently (e.g. oral bisphosphonates; yearly 5mg 
i.v. zoledronic acid; bi-yearly 60mg s.c. denosumab).
Consequently, the distinctive MRONJ risk of these two patient populations 
reflects on di!erent evaluation of possible “Drug Holiday”.
However, it is to be noted that some special patient subsets escape this 
dichotomy:
- Patients su!ering from RA (Rheumatoid Arthritis), showing higher MRONJ 
risk than osteoporosis patients;
- Cancer patients (i.e. breast and prostate cancer patients) receiving pre-
ventative low-dose antiresorptive drugs due to risk of CTIBL (Cancer 
Treatment Induced Bone Loss), with MRONJ risk next to that of osteo-
porotic patients; 
- Cancer patients receiving both antiangiogenic and high dose antiresorp-
tive drugs, at even higher MRONJ risk than those receiving only antire-
sorptive therapy.
Furthermore, the evaluation for a possible drug holiday has to consider that the 
ONJ risk sensibly depends on drug exposure time (years of administration) and 
the observation time (time since the initial administration) in both two main 
patient populations: active cancer and myeloma patients, and osteoporotic 
patients. 
Finally, a careful imaging study of the patient (i.e. by Computed Tomography 
exams) is recommended before balancing pros and cons of drug holiday 
in case of tooth extraction (or other bone trauma) in a symptomatic patient 
at risk of ONJ.
Practices at risk of inappropriateness
#1 performing dental extraction or oral surgery in patients with active cancer 
and myeloma bone disease and in therapy with i.v. high-dose bisphos-
phonates without concerting any temporary suspension (drug holiday) 
with the prescriber (oncologist / haematologist) 
5th National and 1st International Symposium 355
 
Oral presentations
#2 suspending indiscriminately therapy with antiresorptive drugs (i.e. bisphos-
phonates, denosumab) prescribed for osteoporosis (or its prevention), 
at least in the first three years of assumption, in case of necessity of 
extraction or programmed oral surgery
#3 performing dental extraction or oral surgery in patient with active cancer 
and myeloma bone disease and in therapy with denosumab without 
concerting any temporary suspension (drug holiday) with the prescriber 
(oncologist / haematologist)
Good practices
#1 plan, in cancer patients, combined assessment by prescriber (i.e. high risk 
versus low risk of fracture and other SREs, Skeletal-Related Events) and 
by dentist (i.e. high risk versus low risk of post-extraction complications) 
to determine whether or not the need for precautionary suspension of 
i.v. high-dose bisphosphonate, before and after the dental management. 
This combined assessment is mandatory in the absence of univocal data 
on the e"cacy and need to suspend zoledronic acid or other bisphos-
phonates to reduce the risk of ”post-extraction” ONJ, and in consideration 
of conflicting data on the anti-angiogenic e!ect of zoledronic acid [1–4].
#2 plan, in osteometabolic patients, combined assessment by prescriber (i.e. 
high risk versus low risk of fracture)* and by dentist (i.e. high risk versus 
low risk of post-extraction complications) to determine whether or not 
the need for precautionary suspension of the drug, before and after the 
dental procedure. In particular, to evaluate mutually the risk-benefit ratio 
(probability of fracture** versus probability of ONJ) if the therapy continues 
for over three years.
#3 plan, in cancer patients, combined assessment by prescriber (i.e., high risk 
versus low risk of fracture and other SREs, Skeletal-Related Events) and 
by dentist (i.e. high risk versus low risk of post-extraction complications) 
to determine whether or not the need for precautionary suspension 
of denosumab, before and after the dental management, with careful 
monitoring of a possible “rebound” e!ect after discontinuation of deno-
sumab. This is mandatory in the absence of univocal data on the e"cacy 
and on the need to suspend denosumab to reduce the risk of ONJ after 
surgical procedures. We remind what reported in one recent myeloma 
trial of denosumab versus zoledronic acid: “administration of the study 
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drug (subcutaneous and intravenous) was withheld 30 days before any 
elective invasive oral or dental procedures and complete until mucosal 
healing occurred” [8-10].
F.  Practices at risk of inappropriateness in MRONJ therapy and good 
practices
The MRONJ Italian Consensus embraced the principles and good practices 
promoted by the SIPMO/SICMF ONJ Board with respect to therapeutic strat-
egies [11,12]. 
In particular, the following hot topics were discussed and capitalized: #1 
perioperative antibiotic regimen; #2 bone biopsy in patients su!ering from 
clinical-radiological evidence of MRONJ; #3 role of preoperative imag-
ing; #4 anticipated surgery versus planned exfoliation (self-sequestration); 
#5 the shaving and smoothing of bone surfaces during surgical therapy; 
#6 surgery-related quality of life issues for MRONJ patients; #7 impact 
of the type of medication on the treatment decision-making of patients 
with BP-related and non-BP related (anti-RankL and/or targeted therapies) 
MRONJ; #8 surgery for asymptomatic MRONJ; and #9 role of bone turn-
over markers for surgery.
Practices at risk of inappropriateness 
#1 forgetting the adoption of adequate perioperative antibiotic regimen in 
case of surgical treatment of MRONJ.
#2 performing a diagnostic bone biopsy, unless bone metastases are 
suspected.
#3 applying of first-level imaging (e.g. dental x-ray and panoramic radiograph) 
only to plan surgical treatment. 
*  The fracture risk can be determined objectively and correctly by applying the DeFRA79 algo-
rithm validated by AIFA (www.defra-osteoporosi.it), Italian version of the FRAX algorithm.
**  The suspension of denosumab determines within the 3-6 following months a rebound of the 
fracture risk especially in patients at high risk of fracture (those provided for denosumab by the 
AIFA therapeutic plan) [5–7].
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#4 awaiting the exfoliation (i.e. self-sequestration) of necrotic exposed bone 
via the use of non-surgical therapies, since this process is unpredictable 
over time.
#5 neglecting shaving and smoothing of the bone surfaces as a mainstay 
of any surgical procedure
#6 banishing the surgical option for MRONJ cancer patients based on general 
statements of residual life expectancy.
#7 merging BP-related and non-BP-related (e.g. anti-RankL and/or targeted 
therapies) MRONJ patients as a whole when considering temporary inter-
ruption of medications for surgical treatment.
#8 adopting surgical treatment of MRONJ in symptomatic cases only. 
#9 relaying on systemic bone turnover markers to predict the success of 
surgical therapies in MRONJ patients.
Good practices
#1 prescribe a broad-spectrum antibiotic regimen as an integral part of sur-
gical treatment: high-dose amoxicillin/clavulanic acid (1000mg TID), plus 
high-dose Metronidazole (500 mg TID), from the day before surgery and 
up to the 10th post-operative day. Alternatives should be used in case of 
reported allergy to penicillin.
#2 perform a diagnostic bone biopsy in case of clinical and radiological 
suspicion of bone metastases to the jaw.
#3 use of second-level imaging, mainly computed tomography (CT), to 
appropriately plan the extent of jawbone disease before surgery.
#4 anticipate surgical treatment whenever indicated, to reduce the surgical 
burden for MRONJ patients and increase the likelihood of long-term 
healing.
#5 always perform the shaving and smoothing of bone surfaces as a mainstay 
of any surgical procedure to prevent further bone exposure.
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#6 plan the surgical treatment of MRONJ on an individual basis, weighing 
the impact and the potential benefit of surgery on the general health 
status of patients.
#7 discuss and plan the temporary interruption of any given medication in 
agreement with the prescriber and based on its pharmacological prop-
erties, before initiating every MRONJ surgical treatment.
#8 adopt the early surgical treatment also in MRONJ asymptomatic patients.
#9 do not rely on systemic bone turnover markers to establish individual treat-
ment algorithm for MRONJ, but carefully examine all potential factors that 
are likely to influence the long-term success of therapies, including the 
underlying disease (cancer or non-cancer) and the type of medication used.
Keywords: MRONJ, ONJ (Osteonecrosis of the Jaws), BRONJ (BisphosPhonate-Related 
Osteonecrosis of the Jaw), risk of inappropriateness, MRONJ Italian Consensus, SIPMO, SIdCO
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